Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation Identifier:
First received: May 14, 2013
Last updated: July 23, 2015
Last verified: July 2015
Test the hypothesis that INCB039110 can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.

Condition Intervention Phase
Metastatic Cancer
Metastatic Pancreatic Cancer
Drug: INCB039110
Drug: Gemcitabine
Drug: nab-paclitaxel
Drug: filgrastim
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Official Title: A Phase 1B/2 Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Safety and tolerability of combination therapy study treatment INCB039110 plus nab-paclitaxel and gemcitabine as measured by the number of participants with adverse events [ Time Frame: Baseline and weekly for Cycle 1 and then Day 1, Week 8 and Week 15 for all subsequent cycles until the End of Treatment visit (approximately 6 months). ] [ Designated as safety issue: Yes ]
  • Identify the Maximum Tolerated Dose (MTD) within a defined dose range for INCB039110 in the treatment regimens administered. [ Time Frame: Each cohort will be observed for a minimum of 28 days. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics of gemcitabine and paclitaxel administered with or without concurrent INCB039110 [ Time Frame: Baseline up to 6 months. ] [ Designated as safety issue: No ]
  • Clinical activity as measured by the greatest decrease in tumor burden compared to baseline. [ Time Frame: Baseline and approximately every two cycles throughout the study until study completion or early termination (approximately 6 months). ] [ Designated as safety issue: No ]

Estimated Enrollment: 65
Study Start Date: June 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INCB039110, gemcitabine, nab-paclitaxel, filgrastim Drug: INCB039110 Drug: Gemcitabine
Other Name: Gemzar®
Drug: nab-paclitaxel
Other Name: Abraxane®
Drug: filgrastim
Other Name: Neupogen®

Detailed Description:

Study Part 1: This is a dose optimization phase designed to find a tolerated regimen that includes identifying the MTD of INCB039110 (within a defined pharmacologic range) in combination with doses of gemcitabine and nab-paclitaxel that have established safety and tolerability in subjects with advanced or metastatic solid tumors.

Study Part 2: This phase will explore the safety and clinical activity of the treatment regimen identified in Part 1 in subjects with advanced or metastatic pancreatic cancer.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumor (Part 1) or pancreatic adenocarcinoma (Part 2)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Received no more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neo-adjuvant and/or adjuvant therapy)
  • Adequate renal, hepatic, and bone marrow function without frequent blood product or hematopoietic growth factor support (eg use of erythropoietin or transfusions > 2 units packed red blood cells every 3 months)
  • Ability to swallow and retain oral medication

Exclusion Criteria:

  • Any known contraindications to the use of a required comedication (gemcitabine or nab-paclitaxel).
  • Evidence of uncontrolled brain metastases or history of uncontrolled seizures.
  • Ongoing radiation therapy and/or radiation therapy administered within 28 days of enrollment or ongoing radiotherapy-related toxicities.
  • Presence of ≥ Grade 2 neuropathy.
  • Inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.
  • Recent (≤ 3 months) history of partial or complete bowel obstruction.
  • Unwillingness to be transfused with blood components.
  • Known history of Hepatitis B or C infection or HIV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01858883

Contact: Incyte Corporation Call Center 1-855-463-3463

United States, Arizona
Active, not recruiting
Scottsdale, Arizona, United States
United States, Arkansas
Fayetteville, Arkansas, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Maryland
Active, not recruiting
Baltimore, Maryland, United States
United States, New York
Lake Success, New York, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
Incyte Corporation
Study Director: Albert Assad, M.D. Incyte Corporation
  More Information

No publications provided

Responsible Party: Incyte Corporation Identifier: NCT01858883     History of Changes
Other Study ID Numbers: INCB 39110-116
Study First Received: May 14, 2013
Last Updated: July 23, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasm Metastasis
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Neoplastic Processes
Pancreatic Diseases
Pathologic Processes
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on November 25, 2015